4D Path President and Chief Technology Officer Tathagata Dasgupta, Ph.D., and Chief Scientific Officer Satabhisa Mukhopadhyay, Ph.D., participated in a Friends of Cancer Research panel discussion alongside other leaders from the fields of digital pathology, genomic diagnostics, and pharmaceuticals to discuss the promise of computational pathology in oncology drug development and clinical care.
The objectives of the discussion and corresponding white paper were to:
- Characterize current and future use of computational pathology in oncology drug development and how they can facilitate clinical research.
- Identify the challenges in current drug and diagnostic co-development and articulate lessons learned to circumvent these in computational pathology.
- Provide proposals to facilitate robust development of computational pathology platforms for oncology drug development, including:
- Outline input and platform performance characteristics to report for optimized transparency.
- Establish a risk classification framework to inform evidentiary needs and performance criteria.
- Establish common reference standards and repositories of reference materials to support future platform development and cross-validation platforms.
Download the Friends of Cancer Research white paper, “Supporting the Application of Computational Pathology in Oncology,” to learn more about the discussion and findings.
